Department of Surgery, Indiana University School of Medicine, 545 Barnhill Dr., EH541, Indianapolis, IN, 46202, USA.
Surg Endosc. 2021 Sep;35(9):5173-5178. doi: 10.1007/s00464-020-08009-1. Epub 2020 Sep 24.
Patients with higher postoperative infection risk undergoing ventral hernia repair (VHR) have limited options for mesh use. Biosynthetic mesh is intended to utilize the durability of synthetic mesh combined with the biocompatibility of biologic mesh. We sought to assess the outcomes of a novel biosynthetic scaffold mesh for VHR in higher risk patients over a 12-month postoperative period.
Two cohorts of 50 consecutive patients who underwent VHR with TELA Bio OviTex biosynthetic or synthetic mesh were retrospectively compared. Endpoints included surgical site occurrence (SSO), readmission rate, and hernia recurrence following VHR at 12 months postoperatively.
OviTex mesh placement was associated with higher risk Ventral Hernia Working Group (VHWG) distribution and more contaminated CDC wound class distribution compared to synthetic mesh placement (VHWG grade 3: 68% vs. 6%, p < 0.001; CDC class > I: 70% vs. 6%, p < 0.001). Additionally, concomitant procedures were performed more often with OviTex mesh placement than synthetic mesh placement (70% vs 10%, p < 0.001). The OviTex mesh performed comparably to synthetic mesh in terms of incidences of SSO (36% vs 22%, p = 0.19), readmission rates (24% vs 14%, p = 0.31), and hernia recurrence (6% vs 12%, p = 0.74). On further evaluation, patients who developed SSO with OviTex mesh (n = 18) had a 17% hernia recurrence whereas those with synthetic mesh (n = 11) had an associated 55% hernia recurrence (p = 0.048).
The OviTex biosynthetic mesh was used in higher risk patients and performed similarly to synthetic mesh in regards to rate of SSO, readmissions, and hernia recurrence. Furthermore, patients who developed SSO with Ovitex mesh were significantly less likely to have hernia recurrence than those with synthetic mesh. Overall, the data suggest that biosynthetic mesh is a more desirable option for definitive hernia repair in higher risk patients.
接受腹疝修补术(VHR)的术后感染风险较高的患者,在使用网片时选择有限。生物合成网片旨在利用合成网片的耐用性和生物网片的生物相容性。我们旨在评估新型生物合成支架网片在 12 个月的术后期间用于高风险患者 VHR 的结果。
回顾性比较了两组各 50 例连续接受 TELA Bio OviTex 生物合成或合成网片 VHR 的患者。终点包括手术部位发生(SSO)、再入院率以及 VHR 术后 12 个月时的疝复发。
与合成网片放置相比,OviTex 网片放置与更高的腹疝工作小组(VHWG)分布和更多污染的 CDC 伤口分类分布相关(VHWG 等级 3:68% vs. 6%,p<0.001;CDC 分类> I:70% vs. 6%,p<0.001)。此外,与合成网片放置相比,OviTex 网片放置时更常进行联合手术(70% vs 10%,p<0.001)。OviTex 网片在 SSO 发生率(36% vs 22%,p=0.19)、再入院率(24% vs 14%,p=0.31)和疝复发率(6% vs 12%,p=0.74)方面与合成网片相当。进一步评估发现,OviTex 网片发生 SSO 的患者(n=18)疝复发率为 17%,而合成网片发生 SSO 的患者(n=11)疝复发率为 55%(p=0.048)。
OviTex 生物合成网片用于高风险患者,在 SSO、再入院和疝复发率方面与合成网片表现相似。此外,Ovitex 网片发生 SSO 的患者疝复发的可能性明显低于合成网片。总体而言,数据表明生物合成网片是高风险患者更理想的确定性疝修复选择。